Literature DB >> 19946780

Clinical features of CIS of the brainstem/cerebellum of the kind seen in MS.

Jaume Sastre-Garriga1, M Tintoré, C Nos, C Tur, J Río, N Téllez, J Castilló, A Horga, H Perkal, M Comabella, A Rovira, X Montalban.   

Abstract

Recognition of multiple sclerosis (MS) attacks relies mostly on clinical assessment. However, their definition based on McDonald criteria refers mostly to timing and when dealing with clinical features is rather ambiguous: "...of the kind seen in multiple sclerosis." This is heightened in clinically isolated syndromes of the brainstem/cerebellum (CISB), where clinical manifestations can be manifold. This study aimed to describe the clinical features of patients with CISB to improve clinical recognition of patients with brainstem manifestations at the onset of their MS. To this end, we conducted a retrospective analysis of case notes of consecutively recruited patients with CISB assessed within 3 months of symptoms onset. Seventy-five patients were included. Most common brainstem-specific symptoms were: diplopia (68%), facial sensory symptoms (32%) and gait disturbance (31%). Adjusting for follow-up times, total number of symptoms and presence of other brainstem-specific symptoms, only the presence of facial sensory symptoms was predictive of (a lower risk of) conversion to clinically definite (CD) MS (Odds ratio: 0.086; p = 0.007). Neither the total number of brainstem-specific, non brainstem-specific nor the sum of both predicted conversion to CDMS. Results indicate that diplopia, facial sensory symptoms and gait disturbance occur in more than 30% of patients with CISB. Facial sensory symptoms are less associated with conversion to CDMS.

Entities:  

Mesh:

Year:  2009        PMID: 19946780     DOI: 10.1007/s00415-009-5403-0

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  12 in total

1.  Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis.

Authors:  M Tintoré; A Rovira; M J Martínez; J Rio; P Díaz-Villoslada; L Brieva; C Borrás; E Grivé; J Capellades; X Montalban
Journal:  AJNR Am J Neuroradiol       Date:  2000-04       Impact factor: 3.825

2.  Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findings.

Authors:  J Sastre-Garriga; M Tintoré; A Rovira; E Grivé; I Pericot; M Comabella; A J Thompson; X Montalban
Journal:  Mult Scler       Date:  2003-02       Impact factor: 6.312

3.  The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course.

Authors:  B G Weinshenker; B Bass; G P Rice; J Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1989-12       Impact factor: 13.501

4.  Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization.

Authors:  Bernard M J Uitdehaag; Ludwig Kappos; Lars Bauer; Mark S Freedman; David Miller; Rupert Sandbrink; Chris H Polman
Journal:  Mult Scler       Date:  2005-04       Impact factor: 6.312

5.  Onset symptoms of multiple sclerosis.

Authors:  C M Poser
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

6.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Authors:  C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; K P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

7.  Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

Authors:  G Comi; M Filippi; F Barkhof; L Durelli; G Edan; O Fernández; H Hartung; P Seeldrayers; P S Sørensen; M Rovaris; V Martinelli; O R Hommes
Journal:  Lancet       Date:  2001-05-19       Impact factor: 79.321

8.  Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b.

Authors:  Chris Polman; Ludwig Kappos; Mark S Freedman; Gilles Edan; Hans-Peter Hartung; David H Miller; Xavier Montalbán; Frederick Barkhof; Krzysztof Selmaj; Bernard M J Uitdehaag; Susanne Dahms; Lars Bauer; Christoph Pohl; Rupert Sandbrink
Journal:  J Neurol       Date:  2007-11-15       Impact factor: 4.849

9.  Polyregional and hemispheric syndromes: a study of these uncommon first attacks in a CIS cohort.

Authors:  R Pelayo; M Tintoré; A Rovira; J Rio; C Nos; E Grivé; N Téllez; M Comabella; X Montalban
Journal:  Mult Scler       Date:  2007-03-15       Impact factor: 6.312

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  3 in total

Review 1.  Medical and Nonstroke Neurologic Causes of Acute, Continuous Vestibular Symptoms.

Authors:  Jonathan A Edlow; David E Newman-Toker
Journal:  Neurol Clin       Date:  2015-08       Impact factor: 3.787

2.  Tongue somatosensory evoked potentials reflect midbrain involvement in patients with clinically isolated syndrome.

Authors:  Magdalena Krbot Skorić; Ivan Adamec; Luka Crnošija; Tereza Gabelić; Barbara Barun; Ivana Zadro; Silva Butković Soldo; Mario Habek
Journal:  Croat Med J       Date:  2016-12-31       Impact factor: 1.351

Review 3.  Cerebellar and/or Brainstem Lesions Indicate Poor Prognosis in Multiple Sclerosis: A Systematic Review.

Authors:  Yuyuan Yang; Meng Wang; Lulu Xu; Meixiang Zhong; Yajuan Wang; Moxin Luan; Xingao Li; Xueping Zheng
Journal:  Front Neurol       Date:  2022-04-29       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.